Honvan Tablet contains Fosfestrol 120 mg, a synthetic estrogen used primarily in the management of advanced prostate cancer. Fosfestrol acts as an anti-androgen by suppressing the production of testosterone, thereby inhibiting the growth of androgen-dependent prostate cancer cells. This medication is indicated for patients with metastatic prostate carcinoma, particularly those who are not candidates for surgical castration or who require hormonal therapy. Upon oral administration, Fosfestrol is rapidly absorbed and converted to diethylstilbestrol, exerting its therapeutic effects by binding to estrogen receptors and reducing luteinizing hormone secretion, leading to decreased testicular testosterone synthesis. Honvan Tablet should be used under strict medical supervision due to potential side effects, including cardiovascular events, thromboembolism, gynecomastia, and gastrointestinal disturbances. Regular monitoring of liver function, cardiovascular status, and hematological parameters is recommended during treatment. Contraindications include known hypersensitivity to estrogens, history of thromboembolic disorders, and severe hepatic impairment. Dosage and duration of therapy should be individualized based on clinical response and tolerability. Honvan Tablet offers a valuable hormonal treatment option in the palliative management of prostate cancer, contributing to symptom control and disease progression delay.